Amgen: cross-border access for the specialty portfolio

Quick orientation

Amgen Inc. is a US-headquartered biotechnology company based in Thousand Oaks, California. The 2023 acquisition of Horizon Therapeutics added a rare-disease and autoimmune franchise (Tepezza, Krystexxa, Uplizna, Tavneos) on top of Amgen's existing cardiovascular (Repatha), oncology (Blincyto, Imdelltra, Kyprolis, Lumakras, Vectibix, Xgeva), bone health (Prolia, Evenity), and inflammation (Otezla, Enbrel legacy) portfolios.

Portfolio in cross-border NPP scope

Repatha (evolocumab)

PCSK9 inhibitor monoclonal antibody approved for primary hyperlipidemia, heterozygous and homozygous familial hypercholesterolemia, and pediatric HeFH age 10 and older. International requests cluster around HoFH patients in MENA and India (where consanguinity-driven HoFH prevalence is higher than the global average) and around adult patients who have failed statin therapy and whose payer denies PCSK9 coverage.

Tepezza (teprotumumab)

IGF-1-receptor inhibitor approved for thyroid eye disease. US WAC for the eight-infusion course runs into the multi-hundred-thousand-dollar range. International requests come overwhelmingly from TED patients in MENA, India, and the Gulf where no other disease-modifying therapy is locally registered.

Uplizna (inebilizumab)

Anti-CD19 monoclonal antibody approved for anti-AQP4-IgG-positive NMOSD and for generalized myasthenia gravis. International requests come from NMOSD and gMG patients in MENA and India where the locally available NMOSD options are limited to off-label rituximab.

Krystexxa (pegloticase)

Pegylated uricase enzyme replacement therapy for refractory chronic gout. International requests come from chronic gout patients in MENA and India who have failed urate-lowering therapy.

Tavneos (avacopan)

Complement C5a receptor antagonist approved for severe active ANCA-associated vasculitis. International requests come from ANCA vasculitis patients in MENA and India where the standard cyclophosphamide and rituximab regimens have failed.

Blincyto (blinatumomab) and Imdelltra (tarlatamab)

Blincyto is a CD19-CD3 bispecific T-cell engager approved across acute lymphoblastic leukemia minimal residual disease and frontline consolidation. Imdelltra is a DLL3-CD3 bispecific approved 2024 for extensive-stage small-cell lung cancer progression after platinum chemotherapy. Cross-border requests come from ALL and SCLC patients in MENA and India where these indications are not yet locally registered.

Lumakras (sotorasib)

KRAS G12C inhibitor approved for KRAS G12C-mutated locally advanced or metastatic NSCLC. International requests come from KRAS G12C-positive NSCLC patients in MENA and India where the mutation-specific therapy is not yet locally registered.

Prolia (denosumab) and Evenity (romosozumab)

Prolia is the every-six-months anti-RANKL osteoporosis agent. Evenity is the anti-sclerostin osteoporosis agent for postmenopausal women at high fracture risk. International requests for Evenity cluster around postmenopausal patients in MENA who have failed bisphosphonates.

Otezla (apremilast)

Oral PDE4 inhibitor approved for plaque psoriasis, psoriatic arthritis, and oral ulcers of Behcet's disease. International requests cluster around Behcet's disease patients in MENA and Turkey-adjacent populations (where Behcet's prevalence is highest globally).

Why patients route Amgen products through cross-border NPP

Three patterns dominate. First, the Horizon-origin rare-disease franchise (Tepezza, Uplizna, Krystexxa, Tavneos) is too new globally for most non-US labels and the patient populations are tertiary-specialist concentrated. Second, HoFH and pediatric FH represent populations where MENA and India consanguinity patterns drive higher prevalence than the global average. Third, Amgen Safety Net Foundation and SureClick patient support are restricted to US residents.

Manufacturer engagement posture

Reserve Meds coordinates Amgen and Horizon-origin US product through DSCSA-compliant specialty wholesaler channels. We are not an authorized Amgen distributor. All Reserve Meds orders are cash-pay at firm-quote pricing.

For Amgen market access teams: Reserve Meds maintains structured demand visibility across rare-disease, oncology, cardiovascular, and bone health franchises. If your group is sizing pre-registration demand in MENA and India, we are open to a structured conversation under NDA.

Common cross-border destinations for the Amgen portfolio

Repatha demand is broad across the Gulf, India, and Egypt. Tepezza concentrates in tertiary thyroid eye disease centers in the UAE, Saudi Arabia, and India. Uplizna tracks NMOSD and gMG specialty neurology centers in India and the Gulf. The oncology franchise (Blincyto, Lumakras, Imdelltra) concentrates in India, Saudi Arabia, UAE, and Egypt. Otezla and Behcet's demand is heavy in Egypt, Saudi Arabia, and Turkey-adjacent populations.

What Reserve Meds provides

For every Amgen product order, Reserve Meds coordinates DSCSA chain-of-custody documentation; cold-chain validated logistics where required; country regulatory pathway expertise covering named-patient import approval, customs clearance, and any required physician declaration; and a single patient-facing coordinator. We do not replace the patient's treating physician. A US-licensed pharmacist reviews every prescription before dispensing.

Next step for patients

Patients or caregivers who have a treating physician's prescription for a Amgen product and want a firm quote can start a request below.

Start a request for a Amgen product

Next step for Amgen teams

If you are on the Amgen access, medical affairs, or international market access team and want to discuss coordinated named-patient program demand from MENA and India, reach us at [email protected]. We will share aggregated demand views under NDA.

Reserved for you.